Study reveals which blood pressure drugs best protect kidney patients from decline

A major nationwide study compared two common drug combinations for kidney disease patients, offering clarity on which approach slows progression and extends survival. The findings could reshape treatment guidelines and reduce the estimated $48 billion annual cost of kidney failure care in the U.S.

Originaltitel: A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality